Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01258010
Other study ID # JFH2011-001
Secondary ID
Status Completed
Phase N/A
First received December 8, 2010
Last updated April 30, 2014
Start date April 2011
Est. completion date April 2014

Study information

Verified date April 2014
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Spinal surgery may be associated with substantial blood loss which often requires erythrocyte transfusion. Transfusion of red blood cells (RBC) is not free of adverse events and has been associated with increased risks of infection, and globally higher morbidity and mortality.

Different techniques have been used to reduce perioperative blood losses and related transfusions. Tranexamic acid has been used successfully in cardiac and hepatic surgery. However, only a few studies have reported on the use of antifibrinolytic drugs in spinal surgery.

This study was designed to assess the efficacy and safety of tranexamic acid in spinal surgery for the reduction of RBC transfusion.

Hypothesis: the infusion of tranexamic acid during spinal surgery will reduce the risk of receiving a RBC transfusion and, in those patients transfused, reduce the number of blood products administered.


Description:

Administration of study drug

The administration of tranexamic acid/placebo will start following the induction of general anesthesia. A bolus dose will be given intravenously over 30 minutes followed by a continuous infusion administered up to 6 hours postoperatively.

Drugs used for anesthesia and postoperative analgesia will be left to the discretion of the attending anesthesiologist. The administration of fluids (crystalloids, colloids and blood products) will be recorded.

Transfusion: The transfusion trigger will be < 80 g/L during surgery if the situation is stable. Transfusion may be initiated according to the attending anesthesiologist if the situation is unstable. In the case of massive bleeding, transfusion will follow our standard institutional protocol. The presence of microvascular bleeding at the surgical site will be assessed by the surgeon. The Cellsaver will not be used.

The transfusion trigger during the postoperative period will be < 80 g/L. Blood losses and the need for transfusion will be recorded from the moment of surgery up to 72 hours postoperatively.

Laboratory testing

Before surgery: hemoglobin and coagulogram values will be recorded.

During surgery: the patient's coagulation status will be assessed using a thromboelastograph (TEG). Thromboelastography is a simple coagulation test that enables evaluation of all components of hemostasis. TEG testing will be performed at the induction of anesthesia and every 2 hours throughout surgery. An additional blood sample for TEG analysis will be collected at the end of surgery if the previous test was performed more than an hour before the end of surgery.

After surgery: laboratory testing for hemoglobin, coagulogram, fibrinogen and d-dimer will be performed in the recovery room. Hemoglobin will also be measured on postoperative days 1, 2 and 3. Blood samples to assess cardiac troponin levels will be collected on postoperative days 1 and 2.

Ultrasound : Patients will have an ultrasound examination of the inferior limbs before discharge from the hospital to detect deep vein thrombosis.

Follow-up The presence of adverse events during the course of the hospital stay will be noted.

At 30 days, patients will be contacted by phone to detect any other adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 99
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Patients aged 18 to 85 years

- Patients undergoing spinal surgery with expected significant blood loss

- American Society of Anesthesiologists physical status(ASA) I to III inclusive

Exclusion Criteria:

- Allergy to tranexamic acid

- Epilepsy

- Minimally invasive surgery

- Unwillingness to receive blood transfusion

- Known coagulopathy/hepatic disease

- Previous thromboembolic events

- Pregnancy

- Renal impairment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Tranexamic Acid
Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
Placebo
Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.

Locations

Country Name City State
Canada Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients transfusions From surgery until 72 hours postoperatively Yes
Primary Number of red blood cell transfusions From surgery until 72 hours postoperatively Yes
Secondary Measured blood losses From surgery until 72 hours postoperatively Yes
Secondary Morbidity Deep vein thrombosis, pulmonary embolism, seizures, myocardial infarction, renal failure From surgery until 30 days postoperatively Yes
Secondary Mortality From surgery until 30 days postoperatively Yes
Secondary Length of stay in the hospital At time of discharge No
Secondary Calculated blood losses From surgery until 72 hours postoperatively Yes
See also
  Status Clinical Trial Phase
Completed NCT03657368 - Ventilation Strategy During General Anesthesia for Orthopedic Surgery N/A
Withdrawn NCT02771041 - Assessment of the Influence of Early Preoperative Consultation on Satisfaction and the Average Length of Stay of Patients Who Underwent Total Hip Arthroplasty N/A
Completed NCT02278627 - Impact of a Technique of Massage During the First Week of Hospitalization on the Recycling of the Mobility of the Knee Further to the Installation of Knee Replacement N/A
Recruiting NCT01205295 - Patient Anxiety and Concern as Predictors for the Perceived Quality and Efficacy of Treatment N/A
Completed NCT01389011 - Perfusion Index (PI) and Pleth Variability Index (PVI) in Patients With Interscalene Blocks in Orthopedic Surgery N/A
Completed NCT01063543 - Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery N/A
Active, not recruiting NCT03629262 - Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery Phase 4
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Completed NCT03532256 - Post-op Crowd Sourcing Health Data Via Text-messaging
Active, not recruiting NCT03366805 - A Patient Education Video Program for Post-Operative Recovery After Upper Extremity Surgery N/A
Completed NCT03769077 - Cycle to Fun - 'Exergames' for Inpatient Rehabilitation for Children/Youth With CP N/A
Recruiting NCT05401058 - Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery N/A
Completed NCT00293631 - Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy Phase 2
Completed NCT05110690 - Behavioral Activation and Medication Optimization for Perioperative Mental Health Feasibility Study N/A
Completed NCT05120739 - Efficacy of CHX Cloths Versus CHX Soaps for Bathes Before Orthopedic Surgery N/A
Completed NCT00702416 - Ultrasound Guidance for Interscalene Brachial Plexus Block Phase 4
Completed NCT00724035 - Ultrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery Phase 4
Completed NCT00192894 - New Methods to Detect a Decrease in Heart Function Phase 4
Completed NCT05424211 - The Effect of Music Therapy on Pain Level and Analgesic Consumption N/A
Withdrawn NCT00269971 - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. Phase 3